Literature DB >> 9494600

Pleural effusion as a significant prognostic factor in non-small cell lung cancer.

T Naito1, H Satoh, H Ishikawa, Y T Yamashita, H Kamma, H Takahashi, M Ohtsuka, S Hasegawa.   

Abstract

UNLABELLED: In non-small cell lung cancer (NSCLC), pleural effusion is a frequently observed complication, and often provides a treatment difficulties. The aim of this study is to evaluate prognostic significance of pleural effusion in patients with NSCLC.
MATERIALS AND METHODS: Seven hundred and eight untreated patients with NSCLC who were consecutively admitted to our department over a 20 year period up to December 1996, were analyzed using uni- and multivariate analyses.
RESULTS: Univariate analysis showed pleural effusion to be a significant prognostic factor for NSCLC, in addition to gender, stage, performance status(PS). Multivariate analysis proved pleural effusion to be one of the significant prognostic factors, especially in patients with poor PS.
CONCLUSION: Adequate palliative care to provide prolonged quality survival remains the primary goal of therapy for patients with poor performance status and pleural effusion until better treatments are developed.

Entities:  

Mesh:

Year:  1997        PMID: 9494600

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  16 in total

1.  Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells.

Authors:  S Yano; H Shinohara; R S Herbst; H Kuniyasu; C D Bucana; L M Ellis; I J Fidler
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

2.  Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion.

Authors:  Georgios T Stathopoulos; Zhiwen Zhu; M Brett Everhart; Ioannis Kalomenidis; William E Lawson; Semra Bilaceroglu; Todd E Peterson; Daphne Mitchell; Fiona E Yull; Richard W Light; Timothy S Blackwell
Journal:  Am J Respir Cell Mol Biol       Date:  2005-10-06       Impact factor: 6.914

3.  Talc pleurodesis improves survival of patients with malignant pleural effusions: case-control study.

Authors:  Marta Korsic; Sonja Badovinac; Branka Cucevic; Zoran Janevski
Journal:  Wien Klin Wochenschr       Date:  2015-04-10       Impact factor: 1.704

4.  Staging of lung cancer in a tertiary care setting in Sri Lanka, using TNM 7th edition. A comparison against TNM6.

Authors:  Dinesh L B Dassanayake; Thushara M Muthunayake; Kapila H M P Senevirathna; Anoma Siribaddana
Journal:  BMC Res Notes       Date:  2012-03-14

5.  Endostatin levels in exudative pleural effusions.

Authors:  M Sumi; K Kagohashi; H Satoh; H Ishikawa; Y Funayama; K Sekizawa
Journal:  Lung       Date:  2003 Nov-Dec       Impact factor: 2.584

6.  Diagnostic and prognostic significance of lysophosphatidic acid in malignant pleural effusions.

Authors:  Cui-Qing Bai; Yan-Wen Yao; Chun-Hua Liu; He Zhang; Xiao-Bing Xu; Jun-Li Zeng; Wen-Jun Liang; Wen Yang; Yong Song
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

7.  Adequacy of pleural fluid cytology for comprehensive molecular analysis of lung adenocarcinoma: Experience of a large health-care system.

Authors:  Siddhartha Dilip Dalvi; Karen Chau; Sujata Sajjan; Baidarbhi Chakraborty; Priyanka Karam; Seema Khutti; Cecilia Gimenez; Kasturi Das
Journal:  Cytojournal       Date:  2022-02-04       Impact factor: 2.091

8.  Clinico- pathological profile and course of malignant pleural effusion in a tertiary care teaching hospital in western U.P. with special reference to lung cancer.

Authors:  Anurag Agrawal; Rajeev Tandon; Lalit Singh; Aakanksha Chawla
Journal:  Lung India       Date:  2015 Jul-Aug

9.  Important prognostic factors for survival in patients with malignant pleural effusion.

Authors:  Mauro Musa Zamboni; Cyro Teixeira da Silva; Rodrigo Baretta; Edson Toscano Cunha; Gilberto Perez Cardoso
Journal:  BMC Pulm Med       Date:  2015-03-28       Impact factor: 3.317

10.  Non-significant efficacy of icotinib plus pleurodesis in epidermal growth factor receptor positive mutant lung cancer patients after malignant pleural effusion drainage compared to icotinib alone.

Authors:  Yunhua Xu; Wangsheng Fang; Bingye Cheng; Shanshan Chen; Linping Gu; Li Zhu; Yan Pan; Zhen Zhou
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.